2021
B-cell lymphoma 6 expression is not associated with live birth in a normal responder in vitro fertilization population
Klimczak AM, Herlihy NS, Scott CS, Hanson BM, Kim JG, Titus S, Seli E, Scott RT. B-cell lymphoma 6 expression is not associated with live birth in a normal responder in vitro fertilization population. Fertility And Sterility 2021, 117: 351-358. PMID: 34809978, DOI: 10.1016/j.fertnstert.2021.09.036.Peer-Reviewed Original ResearchConceptsB-cell lymphoma 6 (Bcl6) expressionLive birth groupLive birthsFertilization populationNormal respondersBirth groupProportion of patientsLive birth ratePopulation of patientsEuploid embryo transferCase-control studyEndometrial tissue samplesPreimplantation genetic testingGroup of womenIVF stimulationMean HSCOREIVF outcomesInfertility centerIVF successMAIN OUTCOMEGroup 2Group 1Embryo transferPatientsClinical decision
2019
Gonadotropin-Releasing Hormone Analogs for Gonadal Protection During Gonadotoxic Chemotherapy: A Systematic Review and Meta-Analysis
Sofiyeva N, Siepmann T, Barlinn K, Seli E, Ata B. Gonadotropin-Releasing Hormone Analogs for Gonadal Protection During Gonadotoxic Chemotherapy: A Systematic Review and Meta-Analysis. Reproductive Sciences 2019, 26: 939-953. PMID: 30270741, DOI: 10.1177/1933719118799203.Peer-Reviewed Original ResearchConceptsGonadotropin-releasing hormone analogueSystematic reviewGonadotoxic chemotherapyHormone analogueRisk ratioGnRH agonist-treated patientsGonadotropin-Releasing Hormone AnalogLow-quality evidenceReproductive-aged womenConfidence intervalsSignificant protective effectGonadoprotective effectPresent systematic reviewGnRHa cotreatmentGonadal protectionSupradiaphragmatic radiotherapyCohort studyTrials RegistryGnRHa administrationMenstrual resumptionAutoimmune diseasesSubgroup analysisBreast cancerProtective effectHematological malignancies
2015
Ovarian Aging
Seli E. Ovarian Aging. Seminars In Reproductive Medicine 2015, 33: 375-376. PMID: 26565386, DOI: 10.1055/s-0035-1567817.Peer-Reviewed Original ResearchOocyte Cryopreservation as a Preventive Measure for Age-Related Fertility Loss
Cil AP, Turkgeldi L, Seli E. Oocyte Cryopreservation as a Preventive Measure for Age-Related Fertility Loss. Seminars In Reproductive Medicine 2015, 33: 429-435. PMID: 26562287, DOI: 10.1055/s-0035-1567819.Peer-Reviewed Original ResearchConceptsAge-related declineOocyte cryopreservationAge-related fertility lossGood ovarian reserveFertility preservation strategiesPublic health campaignsPreconceptional counselingOvarian reserveAdvanced ageHealth campaignsPreventive measuresHealth informationMedical professionalsLater stagesWomenYoung adolescentsPreservation strategiesPatientsFertility lossIncidencePublic awarenessStrategies for Controlled Ovarian Stimulation in the Setting of Ovarian Aging
Ata B, Seli E. Strategies for Controlled Ovarian Stimulation in the Setting of Ovarian Aging. Seminars In Reproductive Medicine 2015, 33: 436-448. PMID: 26562286, DOI: 10.1055/s-0035-1567818.Peer-Reviewed Original ResearchConceptsControlled ovarian stimulationOvarian agingOvarian stimulationPossible side effects profileShort GnRH agonist protocolGonadotropin-releasing hormone antagonistGnRH agonist protocolTotal gonadotropin consumptionIU/daySide effect profileCost of medicationsGrowth hormone supplementationHigh-quality evidenceTransdermal testosterone administrationDuration of stimulationQuality of oocytesAppropriate first choiceAgonist protocolCOS protocolsEstradiol primingGonadotropin consumptionGonadotropin dosageEffect profileHormone antagonistHormone supplementation
2014
The impact of assisted reproductive technologies on genomic imprinting and imprinting disorders
Uyar A, Seli E. The impact of assisted reproductive technologies on genomic imprinting and imprinting disorders. Current Opinion In Obstetrics & Gynecology 2014, 26: 210-221. PMID: 24752003, PMCID: PMC4123998, DOI: 10.1097/gco.0000000000000071.Peer-Reviewed Original ResearchConceptsRelevant clinical dataReproductive technology proceduresConclusive clinical trialsBeckwith-Wiedemann syndromeCase seriesLarge registriesClinical trialsART proceduresClinical dataHigh prevalenceGeneral populationLow prevalenceART usePotential associationGenomic imprintingGene expressionDisordersEarly embryo developmentReproductive technologiesAllele-specific gene expressionFurther studiesTechnology proceduresPrevalenceImprinted gene expressionImprinting disorders
2002
Should patients with polycystic ovarian syndrome be treated with metformin?
Seli E, Duleba AJ. Should patients with polycystic ovarian syndrome be treated with metformin? Human Reproduction 2002, 17: 2230-2236. PMID: 12202407, DOI: 10.1093/humrep/17.9.2230.Peer-Reviewed Original ResearchConceptsPolycystic ovarian syndromeTreatment of PCOSInsulin-lowering agentsOvarian syndromePathogenesis of PCOSType 2 diabetes mellitusPromising therapeutic profileEarly spontaneous miscarriageOral antihyperglycaemic agentsInsulin-sensitizing drugsType 2 diabetesRisk of developmentImportant aetiologic factorPlasminogen activator inhibitorSerum lipidsDiabetes mellitusCardioprotective effectsAetiologic factorsAntihyperglycaemic agentsInsulin resistanceSpontaneous miscarriageMetforminTherapeutic profileActivator inhibitorTreatment